TTY Biopharm Company Limited reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 1,059.93 million compared to TWD 1,024.44 million a year ago. Net income was TWD 253.36 million compared to TWD 222.43 million a year ago. Basic earnings per share from continuing operations was TWD 1.02 compared to TWD 0.89 a year ago. Diluted earnings per share from continuing operations was TWD 1.02 compared to TWD 0.89 a year ago. For the nine months, sales was TWD 3,067.16 million compared to TWD 3,019.01 million a year ago. Net income was TWD 488.38 million compared to TWD 661.56 million a year ago. Basic earnings per share from continuing operations was TWD 1.96 compared to TWD 2.66 a year ago. Diluted earnings per share from continuing operations was TWD 1.96 compared to TWD 2.66 a year ago.